At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, 10 important areas of controversy in advanced prostate cancer management were identified and discussed, and experts voted on 123 predefined consensus questions. The full report of the results is summarised here.
Bibliographical noteFunding Information:
Although there was a range of opinions regarding the starting dose of chemotherapy in patients of East Asian ethnicity, 60% of panellists recommended starting chemotherapy at a reduced dose. This strategy is supported by the experience of physicians from the Asia-Pacific region and by limited studies. Although no large prospective clinical trials have compared dosing strategies (eg, a reduced dose vs a full dose with G-CSF support) in this population, the available literature suggests that antitumour activity is comparable, even if a reduced dose is used [174,175] .
© 2020 The Authors
- Advanced prostate cancer
- Castration-naïve prostate cancer
- Castration-resistant prostate cancer
- High-risk localised prostate cancer
- Hormone-sensitive prostate cancer
- Oligometastatic prostate cancer
- Overall survival
- Progression-free survival
- Prostate cancer treatment
- Tumour genomic profiling